JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive: Bcr-Abl/Jak2/Stat5 activity in CML leads to increased expression of genes driving promoting survival, cell cycle progression, and oncogenic signaling pathways [5, 12–14].